Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma  

作　　者：Aswathy R Devan Keechilat Pavithran Bhagyalakshmi Nair Maneesha Murali Lekshmi R Nath 

机构地区：[1]Department of Pharmacognosy,Amrita School of Pharmacy,Amrita Vishwa Vidyapeetham,AIMS Health Science Campus,Kochi 682041,Kerala,India [2]Department of Medical Oncology and Hematology,Amrita Institute of Medical Sciences and Research Centre,Amrita Vishwa Vidyapeetham,Kochi 682041,Kerala,India

出　　处：《World Journal of Gastroenterology》2022年第36期5250-5264,共15页世界胃肠病学杂志（英文版）

基　　金：Supported by the Amrita Vishwa Vidyapeetham SEED grant (K-PHAR-22-662)

摘　　要：Transforming growth factor-beta(TGF-β)is a multifunctional cytokine that performs a dual role as a tumor suppressor and tumor promoter during cancer progression.Among different ligands of the TGF-βfamily,TGF-β1 modulates most of its biological outcomes.Despite the abundant expression of TGF-β1 in the liver,steatosis to hepatocellular carcinoma(HCC)progression triggers elevated TGF-β1 levels,contributing to poor prognosis and survival.Additionally,elevated TGF-β1 levels in the tumor microenvironment create an immunosuppressive stage via various mechanisms.TGF-β1 has a prime role as a diagnostic and prognostic biomarker in HCC.Moreover,TGF-β1 is widely studied as a therapeutic target either as monotherapy or combined with immune checkpoint inhibitors.This review provides clinical relevance and up-to-date information regarding the potential of TGF-β1 in diagnosis,prognosis,and therapy against HCC.

关 键 词：Transforming growth factor-beta 1 Inflammation IMMUNOSUPPRESSION FIBROGENESIS Hepatocellular carcinoma Biomarker IMMUNOTHERAPY 

分 类 号：R735.7[医药卫生—肿瘤]